- Home
- RETO vs BCTX Comparison
RETO vs BCTX Comparison
Compare RETO & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- BCTX
- Stock Information
- Founded
- RETO 1999
- BCTX 2014
- Country
- RETO China
- BCTX Canada
- Employees
- RETO N/A
- BCTX N/A
- Industry
- RETO Multi-Sector Companies
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- RETO Consumer Discretionary
- BCTX Health Care
- Exchange
- RETO Nasdaq
- BCTX Nasdaq
- Market Cap
- RETO 24.7M
- BCTX 23.5M
- IPO Year
- RETO 2017
- BCTX N/A
- Fundamental
- Price
- RETO $2.09
- BCTX $2.96
- Analyst Decision
- RETO
- BCTX Strong Buy
- Analyst Count
- RETO 0
- BCTX 1
- Target Price
- RETO N/A
- BCTX $32.00
- AVG Volume (30 Days)
- RETO 41.2K
- BCTX 355.7K
- Earning Date
- RETO 07-07-2025
- BCTX 06-16-2025
- Dividend Yield
- RETO N/A
- BCTX N/A
- EPS Growth
- RETO N/A
- BCTX N/A
- EPS
- RETO N/A
- BCTX N/A
- Revenue
- RETO $1,828,976.00
- BCTX N/A
- Revenue This Year
- RETO N/A
- BCTX N/A
- Revenue Next Year
- RETO N/A
- BCTX N/A
- P/E Ratio
- RETO N/A
- BCTX N/A
- Revenue Growth
- RETO N/A
- BCTX N/A
- 52 Week Low
- RETO $1.91
- BCTX $2.78
- 52 Week High
- RETO $18.20
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- RETO 29.05
- BCTX 44.63
- Support Level
- RETO $3.05
- BCTX $2.78
- Resistance Level
- RETO $3.15
- BCTX $3.16
- Average True Range (ATR)
- RETO 0.25
- BCTX 0.19
- MACD
- RETO -0.07
- BCTX -0.01
- Stochastic Oscillator
- RETO 31.45
- BCTX 40.24
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly-ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation and construction of urban ecological environments for capturing, controlling and re-using rainwater. It operates through four segments namely Machinery and Equipment sales, Construction materials sales, Municipal Construction Projects, and Technology Consulting and other services. The company earns its revenue from Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.